MXPA04004075A - Compuesto y metodo para tratamiento de vejiga hiperactiva. - Google Patents

Compuesto y metodo para tratamiento de vejiga hiperactiva.

Info

Publication number
MXPA04004075A
MXPA04004075A MXPA04004075A MXPA04004075A MXPA04004075A MX PA04004075 A MXPA04004075 A MX PA04004075A MX PA04004075 A MXPA04004075 A MX PA04004075A MX PA04004075 A MXPA04004075 A MX PA04004075A MX PA04004075 A MXPA04004075 A MX PA04004075A
Authority
MX
Mexico
Prior art keywords
compounds
treatment
overactive bladder
disclosed
methods
Prior art date
Application number
MXPA04004075A
Other languages
English (en)
Inventor
Herzog Keith
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA04004075A publication Critical patent/MXPA04004075A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Abstract

La presente invencion se refiere a compuestos que se unen a NK2R de conformidad con la formula (I), que son utiles para el tratamiento o prevencion de la VHA o la IU en mamiferos, particularmente seres humanos, en donde, en dichos compuestos, D, A, R1, R3, y R4 son como los definidos en la descripcion. Tambien se describen sales farmaceuticamente aceptables de los compuestos, metodos de uso de los compuestos, ya sea por si solos o en combinacion con otros agentes farmacologicos, y composiciones farmaceuticas utiles en la practica de los metodos de la presente invencion.
MXPA04004075A 2001-11-02 2002-11-01 Compuesto y metodo para tratamiento de vejiga hiperactiva. MXPA04004075A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0103795A SE0103795D0 (sv) 2001-11-02 2001-11-02 Compounds and method for the treatment of överactive bladder
PCT/SE2002/001991 WO2003037889A1 (en) 2001-11-02 2002-11-01 Compounds and method for the treatment of overactive bladder

Publications (1)

Publication Number Publication Date
MXPA04004075A true MXPA04004075A (es) 2004-07-23

Family

ID=20285984

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04004075A MXPA04004075A (es) 2001-11-02 2002-11-01 Compuesto y metodo para tratamiento de vejiga hiperactiva.

Country Status (16)

Country Link
US (1) US7368461B2 (es)
EP (1) EP1444220B1 (es)
JP (1) JP2005511571A (es)
KR (1) KR20040053239A (es)
CN (1) CN1610676A (es)
AT (1) ATE353886T1 (es)
BR (1) BR0213832A (es)
CA (1) CA2465429A1 (es)
DE (1) DE60218203T2 (es)
ES (1) ES2282491T3 (es)
IL (1) IL161600A0 (es)
MX (1) MXPA04004075A (es)
NO (1) NO20042138L (es)
SE (1) SE0103795D0 (es)
WO (1) WO2003037889A1 (es)
ZA (1) ZA200403206B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200508221A (en) 2003-06-13 2005-03-01 Astrazeneca Ab New azetidine compounds
DE102004001873A1 (de) * 2004-01-14 2005-09-29 Bayer Healthcare Ag Cyanopyrimidinone
WO2006121389A1 (en) * 2005-05-10 2006-11-16 Astrazeneca Ab Use of a neurokinin-2 receptor antagonist for treating or preventing detrusor overactivity
AR057828A1 (es) 2005-09-29 2007-12-19 Astrazeneca Ab Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica
US8106208B2 (en) 2006-05-18 2012-01-31 Albireo Ab Benzamide compounds that act as NK receptor antagonists
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
CN112915266B (zh) * 2021-02-05 2021-11-09 武汉磁济科技有限公司 一种人工膀胱铁磁复合体及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9321557D0 (en) * 1992-11-03 1993-12-08 Zeneca Ltd Carboxamide derivatives
GB9310713D0 (en) 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
GB9317104D0 (en) * 1993-08-17 1993-09-29 Zeneca Ltd Therapeutic heterocycles
GB9322643D0 (en) * 1993-11-03 1993-12-22 Zeneca Ltd Lactam derivatives
US6008223A (en) 1994-10-27 1999-12-28 Zeneca Limited Therapeutic compounds
GB9421709D0 (en) * 1994-10-27 1994-12-14 Zeneca Ltd Therapeutic compounds
GB9505084D0 (en) 1995-03-14 1995-05-03 Pfizer Ltd Benzamide derivative
GB9922519D0 (en) * 1998-10-07 1999-11-24 Zeneca Ltd Compounds
GB9924141D0 (en) 1998-10-30 1999-12-15 Zeneca Ltd Treatment of gastric asthma
EP1136472A4 (en) * 1998-12-04 2002-08-07 Viromax L L C ARYL- AND HETEROARYLAMIDES OF CARBOALCOXYSULFANILIC ACIDS
GB9826941D0 (en) 1998-12-09 1999-02-03 Zeneca Pharmaceuticals Compounds
GB0015246D0 (en) 2000-06-22 2000-08-16 Astrazeneca Ab Method for the treatment of urinary incontinence

Also Published As

Publication number Publication date
EP1444220B1 (en) 2007-02-14
EP1444220A1 (en) 2004-08-11
SE0103795D0 (sv) 2001-11-02
JP2005511571A (ja) 2005-04-28
BR0213832A (pt) 2004-08-31
DE60218203T2 (de) 2008-01-03
US20050203113A1 (en) 2005-09-15
ATE353886T1 (de) 2007-03-15
NO20042138L (no) 2004-05-25
IL161600A0 (en) 2004-09-27
CA2465429A1 (en) 2003-05-08
WO2003037889A8 (en) 2004-05-06
ZA200403206B (en) 2005-02-22
ES2282491T3 (es) 2007-10-16
US7368461B2 (en) 2008-05-06
CN1610676A (zh) 2005-04-27
DE60218203D1 (de) 2007-03-29
KR20040053239A (ko) 2004-06-23
WO2003037889A1 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
WO2006044362A3 (en) N-sulfonylpiperidine cannabinoid receptor 1 antagonists
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
MXPA04008772A (es) Composiciones de clorhidrato de naltrexona.
WO2003037271A3 (en) Compounds, pharmaceutical compositions and methods of use therefor
TW200503708A (en) Gyrase inhibitors and uses thereof
AU1816901A (en) Benzimidazole compounds having nociceptin receptor affinity
DZ3186A1 (fr) Ptéridinones utilisées comme inhibiteurs de kinase.
WO2005079756A3 (en) Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
WO2004098494A3 (en) Compounds, compositions, and methods
WO2005084654A3 (en) Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
DE602006019754D1 (de) Verfahren und zusammensetzung, die immunomodulatorische verbindungen zur behandlung von mit niedrigen plasmaleptin-spiegeln in zusammenhang stehenden störungen verwenden
WO2004064832A3 (en) Methods for treating joint pain or improving sleep using an estrogen agonist/antagonist
TW200733963A (en) Cough inhibitor
TW200502234A (en) Pyridyloxymethyl and benzisoxazole azabicyclic derivatives
WO2001039723A3 (en) Triazospiro compounds having nociceptin receptor affinity
MXPA02000330A (es) Pirrolidinas y piperidinas neurotroficas y composiciones y metodos relacionados.
AU2003286486A8 (en) Methods and compositions for immunization against hiv
MXPA04004075A (es) Compuesto y metodo para tratamiento de vejiga hiperactiva.
WO2003057213A3 (en) Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor
WO2004078180A3 (en) Naaladase inhibitors for treating opioid tolerance
MXPA04004071A (es) Metodo para tratamiento de vejiga hiperactiva.
GB0015246D0 (en) Method for the treatment of urinary incontinence
DE60236927D1 (de) Suchtpraevention in der schmerzbehandlung mit gamma vinyl gaba
MXPA03004111A (es) Composiciones de n-(1 -metiletilaminocarbonil)-4 -(3-metilfenilamino) -3-piridil-sulfonamida y oligosacaridos ciclicos con una mayor liberacion.